GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Spero Therapeutics Inc (STU:2HA) » Definitions » EPS (Diluted)

Spero Therapeutics (STU:2HA) EPS (Diluted) : €0.40 (TTM As of Mar. 2024)


View and export this data going back to 2019. Start your Free Trial

What is Spero Therapeutics EPS (Diluted)?

Spero Therapeutics's Earnings per Share (Diluted) for the three months ended in Mar. 2024 was €-0.22. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was €0.40.

Spero Therapeutics's EPS (Basic) for the three months ended in Mar. 2024 was €-0.22. Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2024 was €0.40.

Spero Therapeutics's EPS without NRI for the three months ended in Mar. 2024 was €-0.22. Its EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2024 was €0.47.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 9 years, Spero Therapeutics's highest 3-Year average EPS without NRI Growth Rate was 42.40% per year. The lowest was -18.50% per year. And the median was 5.20% per year.


Spero Therapeutics EPS (Diluted) Historical Data

The historical data trend for Spero Therapeutics's EPS (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Spero Therapeutics EPS (Diluted) Chart

Spero Therapeutics Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EPS (Diluted)
Get a 7-Day Free Trial Premium Member Only -3.02 -2.89 -2.58 -1.16 0.39

Spero Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EPS (Diluted) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.23 -0.21 -0.06 0.89 -0.22

Competitive Comparison of Spero Therapeutics's EPS (Diluted)

For the Biotechnology subindustry, Spero Therapeutics's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Spero Therapeutics's PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Spero Therapeutics's PE Ratio distribution charts can be found below:

* The bar in red indicates where Spero Therapeutics's PE Ratio falls into.



Spero Therapeutics EPS (Diluted) Calculation

EPS (Diluted) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Diluted EPS takes into account all of the outstanding dilutive securities that could potentially be exercised (such as stock options and convertible preferred stock) and shows how such an action would impact earnings per share.

Spero Therapeutics's Diluted EPS for the fiscal year that ended in Dec. 2023 is calculated as

Diluted EPS (A: Dec. 2023 ) = (Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(20.913-0)/52.989
=0.39

Spero Therapeutics's Diluted EPS for the quarter that ended in Mar. 2024 is calculated as

Diluted EPS (Q: Mar. 2024 )=(Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-11.655-0)/53.524
=-0.22

EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.40

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Spero Therapeutics  (STU:2HA) EPS (Diluted) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Spero Therapeutics EPS (Diluted) Related Terms

Thank you for viewing the detailed overview of Spero Therapeutics's EPS (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.


Spero Therapeutics (STU:2HA) Business Description

Traded in Other Exchanges
Address
675 Massachusetts Avenue, 14th Floor, Cambridge, MA, USA, 02139
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate, being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.

Spero Therapeutics (STU:2HA) Headlines

No Headlines